Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design

被引:100
作者
Bressi, JC
Verlinde, CLMJ
Aronov, AM
Le Shaw, M
Shin, SS
Nguyen, LN
Suresh, S
Buckner, FS
Van Voorhis, WC
Kuntz, ID
Hol, WGJ
Gelb, MH [1 ]
机构
[1] Univ Washington, Dept Chem, Seattle, WA 98195 USA
[2] Univ Washington, Dept Biochem, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA 98195 USA
[4] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA
[5] Biomol Struct Ctr, Seattle, WA 98195 USA
[6] Howard Hughes Med Inst, Seattle, WA 98195 USA
[7] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA
关键词
D O I
10.1021/jm000472o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In our continuation of the structure-based design of anti-trypanosomatid drugs, parasite-selective adenosine analogues were identified as low micromolar inhibitors of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Crystal structures of Trypanosoma brucei, Trypanosoma cruzi, Leishmania mexicana, and human GAPDH's provided details of how the adenosyl moiety of NAD(+) interacts with the proteins, and this facilitated the understanding of the relative affinities of a series of adenosine analogues for the various GAPDH's. From exploration of modifications of the naphthalenemethyl and benzamide substituents of a lead compound, N-6(1-naphthalenemethyl)-2'-deoxy-2'-(3-methoxybenzamido) adenosine (6e), N-6-(substituted-naphthalenemethyl)-2'-deoxy-2'-(substituted-benzamido)adenosine analogues were investigated. N-6(1-Naphthalenemethyl)-2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (6m), N-6-[1-(3-hydroxynaphthalene)methyl] -2'-deoxy-2'-(3,5-dimethoxybenzamido)adenosine (7m), N-6-[1-(3-methoxynaphthalene)methyl]-2'-deoxy-2'-(3,5-dimethoxybenzamido (9m), N-6-(2-naphthalenemethyl)-2'-deoxy-2'-(3-methoxybenzamido)adenosine (11e), and N-6-(2-naphthalenemethyl)-2'deoxy-2'-(3,5-dimethoxybenzamido)adenosine (11m) demonstrated a 2- to 3-fold improvement over se and a 7100- to 25000-fold improvement over the adenosine template. IC(50)s of these compounds were in the range 2-12 muM for T. brucei, T. cruzi, and L. mexicana GAPDH's, and these compounds did not inhibit mammalian GAPDH when tested at their solubility limit. To explore more thoroughly the structure-activity relationships of this class of compounds, a library of 240 N-6-(substituted)-2'-deoxy-2'-(amido)aden analogues was generated using parallel solution-phase synthesis with N-6 and C2' substituents chosen on the basis of computational docking scores. This resulted in the identification of 40 additional compounds that inhibit parasite GAPDH's in the low micromolar range. We also explored adenosine analogues containing 5'-amido substituents and found that 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine (49) displays an IC50 of 60-100 muM against the three parasite GAPDH's.
引用
收藏
页码:2080 / 2093
页数:14
相关论文
共 48 条
[1]  
Allen F.H., 1993, CHEM AUTOMAT NEWS, V8, P31
[2]   Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase [J].
Aronov, AM ;
Suresh, S ;
Buckner, FS ;
Van Voorhis, WC ;
Verlinde, CLMJ ;
Opperdoes, FR ;
Hol, WGJ ;
Gelb, MH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4273-4278
[3]   Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design [J].
Aronov, AM ;
Verlinde, CLMJ ;
Hol, WGJ ;
Gelb, MH .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4790-4799
[4]   Rational design of selective submicromolar inhibitors of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase [J].
Aronov, AM ;
Munagala, NR ;
de Montellano, PRO ;
Kuntz, ID ;
Wang, CC .
BIOCHEMISTRY, 2000, 39 (16) :4684-4691
[5]   Activation method to prepare a highly reactive acylsulfonamide ''safety-catch'' linker for solid-phase synthesis [J].
Backes, BJ ;
Virgilio, AA ;
Ellman, JA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (12) :3055-3056
[6]   What controls glycolysis in bloodstream form Trypanosoma brucei? [J].
Bakker, BM ;
Michels, PAM ;
Opperdoes, FR ;
Westerhoff, HV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (21) :14551-14559
[7]   Glycolysis in bloodstream form Trypanosoma brucei can be understood in terms of the kinetics of the glycolytic enzymes [J].
Bakker, BM ;
Michels, PAM ;
Opperdoes, FR ;
Westerhoff, HV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) :3207-3215
[8]   Compartmentation protects trypanosomes from the dangerous design of glycolysis [J].
Bakker, BM ;
Mensonides, FIC ;
Teusink, B ;
van Hoek, P ;
Michels, PAM ;
Westerhoff, HV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (05) :2087-2092
[9]   Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors [J].
Bohacek, R ;
DeLombaert, S ;
McMartin, C ;
Priestle, J ;
Grutter, M .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (35) :8231-8249
[10]   Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase [J].
Buckner, FS ;
Verlinde, CLMJ ;
LaFlamme, AC ;
vanVoorhis, WC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2592-2597